Charles Schwab Investment Management Inc. Sells 144,686 Shares of Fulcrum Therapeutics, Inc. $FULC

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Fulcrum Therapeutics by 27.5%, selling 144,686 shares and owning 381,359 shares at the end of the first quarter.
• Fulcrum Therapeutics' recent quarterly earnings showed a loss of ($0.28) per share, slightly better than analysts' estimates of ($0.29) per share.
• Recent analyst ratings for Fulcrum Therapeutics have varied, with one firm downgrading to a "sell" rating and another raising its price target to $12.00, reflecting mixed investor sentiment.

Charles Schwab Investment Management Inc. reduced its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 27.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 381,359 shares of the company's stock after selling 144,686 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.71% of Fulcrum Therapeutics worth $1,098,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in FULC. Suvretta Capital Management LLC boosted its position in shares of Fulcrum Therapeutics by 182.3% during the fourth quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock worth $15,691,000 after buying an additional 2,155,675 shares during the period. Woodline Partners LP lifted its position in Fulcrum Therapeutics by 110.3% in the fourth quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock worth $6,629,000 after purchasing an additional 739,713 shares during the period. LMR Partners LLP lifted its position in Fulcrum Therapeutics by 367.2% in the fourth quarter. LMR Partners LLP now owns 112,500 shares of the company's stock worth $529,000 after purchasing an additional 154,600 shares during the period. Northern Trust Corp lifted its position in shares of Fulcrum Therapeutics by 25.1% during the 4th quarter. Northern Trust Corp now owns 710,321 shares of the company's stock valued at $3,339,000 after acquiring an additional 142,578 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth $658,000. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Price Performance

NASDAQ:FULC traded up $0.11 during trading hours on Wednesday, reaching $6.52. The company's stock had a trading volume of 221,586 shares, compared to its average volume of 428,302. The company has a market cap of $352.67 million, a price-to-earnings ratio of -5.34 and a beta of 2.82. Fulcrum Therapeutics, Inc. has a one year low of $2.32 and a one year high of $9.30. The business's 50-day moving average is $7.06 and its 200-day moving average is $5.42.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. On average, sell-side analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on FULC. Leerink Partners raised Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $4.00 to $12.00 in a research note on Friday, May 23rd. Leerink Partnrs raised shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Friday, May 23rd. Piper Sandler reissued an "overweight" rating and set a $9.00 target price (up from $6.00) on shares of Fulcrum Therapeutics in a research note on Thursday, May 29th. Wall Street Zen downgraded shares of Fulcrum Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, Cantor Fitzgerald raised shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a research note on Thursday, May 15th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $7.57.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.